Novo Nordisk has successfully opposed a federal court’s attempt to prevent the FDA from taking action against compounding pharmacies producing copies of its diabetes and obesity medication semaglutide, commonly sold as Ozempic and Wegovy. The FDA can now take measures against members of the Outsourcing Facilities Association for manufacturing unauthorized versions of the drug.
The association argued that shortages of branded treatments persisted after semaglutide was removed from the FDA’s shortage list in February. However, a federal judge has ruled against their request for a preliminary injunction. Compounding pharmacies are permitted to produce generic versions of medications when they are facing supply shortages, as occurred during periods when Ozempic and Wegovy were in short supply. The decision upholds Novo Nordisk’s intellectual property rights and limits the production of unauthorized semaglutide copies by compounding pharmacies.
Source: https://www.statnews.com/2025/04/25/novo-nordisk-semaglutide-ozempic-compounding-fda